Singular Bio

San Francisco, United States Founded: 2012 • Age: 14 yrs Acquired By Invitae
Tools for single molecule detection are developed by Singular Bio.
Annual revenue - Latest available
Total funding $6.6M 2 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Singular Bio

Singular Bio is a company based in San Francisco (United States) founded in 2012 by Hywel Jones was acquired by Invitae in June 2019. Singular Bio has raised $6.58 million across 2 funding rounds from investors including Invitae and The Vertical Group. Singular Bio operates in a competitive market with competitors including Novogene Corporation, Rejuvenate Bio, Source BioScience, Macrogen and Beikang Medical, among others.

  • Headquarter San Francisco, United States
  • Founders Hywel Jones
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $6.58 M (USD)

    in 2 rounds

  • Latest Funding Round
    $6.58 M (USD), Series A

    Feb 12, 2019

  • Investors
    Invitae

    & 1 more

  • Employee Count
    Not available
  • Acquired by
    Invitae

    (Jun 17, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Singular Bio

Singular Bio has successfully raised a total of $6.58M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6.58 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Singular Bio

Singular Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Invitae and The Vertical Group.

All
Venture Fund
Investor Description Founded Year Domain Location
Investments in early and late-stage US companies are made.
Locked Locked Locked
Home-based genetic tests for detecting diseases are provided to individuals.
Locked Locked Locked
Premium access

Investor details for Singular Bio

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Singular Bio

Investments
Premium access

Investment portfolio details for Singular Bio

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Singular Bio

Premium access

Detailed financials for Singular Bio

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Singular Bio Comparisons

Singular Bio Primary company
Description
Tools for single molecule detection are developed by Singula...
Location
San Francisco, United States
Founded Year
2012
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Singular Bio

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Singular Bio

Singular Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novogene Corporation, Rejuvenate Bio, Source BioScience, Macrogen and Beikang Medical, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Genomic services and solutions with NGS expertise are provided.
Locked Locked Locked
Gene-editing platform and anti-aging therapy for dogs are developed.
Locked Locked Locked
Multiple genomic services are provided for analysis and diagnostics.
Locked Locked Locked
Next-generation sequencing and genomics services are provided globally.
Locked Locked Locked
NGS-based diagnostic solutions for neonatal screening are developed.
Locked Locked Locked
Bioinformatics platform for genetic disease analysis is provided.
Premium access

Detailed competitors of Singular Bio

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Singular Bio

Premium access

Complete news archive for Singular Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Singular Bio

Singular Bio was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Singular Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Hywel Jones is the current CEO of Singular Bio. They have also founded this company.

Singular Bio is a funded company, having raised a total of $6.58M across 2 funding rounds to date.

Singular Bio was founded in 2012 in San Francisco, United States, within the biotechnology sector. A proprietary single molecule detection system is provided, where unique measurements are taken for each molecule through the integration of advanced optics, custom molecular biology, and chemistry. The screening platform is utilized for its user-friendly design, flexibility, and scalable throughput, supporting deployment in testing labs of varying sizes across different locations.

Singular Bio's top competitors include Novogene Corporation, Source BioScience and Genewiz.

Singular Bio has 2 investors. Key investors include Invitae, and The Vertical Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available